Industry News

United Kingdom : Hikma announces successful resolution to US FDA warning letter at Eatontown facility
Baxter International to acquire Chapel Hill biotech company for $70 million
FDA approves easy-to-use heroin overdose antidote
Orphan drugs market offers big financial incentives
Meda turns down approach from Mylan
Orphan drugs market offers big financial incentives
Baxter International to acquire Chapel Hill biotech company for $70 million
Novation Recognizes 27 suppliers for excellence in supporting members of VHA, UHC, Children's Hospital Association and Provista
FDA OKs 1st hay fever allergy immunotherapy tablet
Novation Recognizes 27 suppliers for excellence in supporting members of VHA, UHC, Children's Hospital Association and Provista
FDA OKs 1st hay fever allergy immunotherapy tablet
FDA OKs 1st hay fever allergy immunotherapy tablet
FDA approves easy-to-use heroin overdose antidote
RestorGenex Completes Acquisition of Two Biopharmaceutical Companies
Actavis plans to spend $100M on generic drugmaker
RestorGenex Completes Acquisition of Two Biopharmaceutical Companies
Novation Recognizes 27 suppliers for excellence in supporting members of VHA, UHC, Children's Hospital Association and Provista
Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
BioLight Announces IND Filing with FDA for Phase I/IIa Clinical Study of its Controlled Release Latanoprost Insert for the Treatment of Glaucoma
Patients Report Use of MTS Blister Card Improves Confidence in Safely Taking Medications and Reducing Emergency Room Visits
Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B
Abbott Announces FDA Approval of Its Supera Stent to Treat People with Peripheral Artery Disease
Ferring Pharmaceuticals Inc. Receives FDA Approval for the First and Only Mixed Protocol IVF Treatment -- Combines MENOPUR� menotropins for injection... Pharmaceutical Companies
Actavis plans to spend $100M on generic drugmaker